Baxter Expanding Facilities In China To Keep Pace With Exploding Market Growth, Testing A/H1N1 Strain In U.S. For Potential Vaccine
This article was originally published in PharmAsia News
BEIJING - The U.S.-headquartered Baxter International is reinvesting most of the $200 million in revenues it posted in China in 2008 to expand production facilities across the country, even as Baxter's American scientists begin testing a strain of the A/H1N1 virus for a potential vaccine if a pandemic is declared by the World Health Organization
You may also be interested in...
China’s Health System Reforms Set To Spark Hospital Construction Boom And Boost Medical Device Makers
[Editor's note: This is part two in a new series on China's wide-ranging plans to reform the country's health system, including its hospitals, insurance schemes and access to medicines. Part one appeared in PharmAsia News on Oct. 30, 2008.]